A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody–ribonuclease fusion protein targeting the EGF receptor

Stefan Kiesgen1, Nora Liebers1, Martin Cremer1, Ulrich Arnold2, Tobias Weber1, Armin Keller1, Christel Herold-Mende3,4, Gerhard Dyckhoff4, Dirk Jager1, Roland E.Kontermann5, Michaela A. E.Arndt1,6 and Jurgen Krauss1,7 Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany, Institute of Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120 Halle, Germany, Division of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany, Molecular Cell Biology Group, ENT Department, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany, Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany and Present address: Immunotherapy Program, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany